Ketorolac (systemic) vs Ibritumomab

Interacting Drugs
Ketorolac (systemic)
vs
Ibritumomab
Security Level
Minor, Monitor Therapy
Mechanism
Ibritumomab: Antiplatelet Agents may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.
Management
Monitor therapy

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Ketorolac (systemic) vs Ibritumomab